The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Open Higher As Latest BoE Decision Awaited

Thu, 21st Jun 2018 08:35

LONDON (Alliance News) - Stocks in London opened higher for the second day in a row, with investors awaiting the latest monetary policy decision from the Bank of England at midday.Shire was the best performer in the FTSE 100 on positive news from the US Food & Drug Administration, while Dixons Carphone found itself among the best mid-cap performers despite posting a sharp fall in annual profit.The FTSE 100 index was up 0.5%, or 40.93 points, at 7,668.33 early Thursday. The mid-cap FTSE 250 index was up 0.3%, or 64.47 points, at 20,990.85. The AIM All-Share index was also up 0.3% at 1,098.42.The Cboe UK 100 was up 0.3% at 12,995.05, the Cboe UK 250 was also up 0.3% at 19,224.16, and the Cboe UK Small Companies was down 0.2% at 12,869.46.At the top of the FTSE 100 on Thursday was drugmaker Shire, gaining 2.4%. Shire has secured approval from the US Food & Drug Administration to expand the offering of Cinryze to children aged six years and older with hereditary angioedema, a rare disorder characterized by recurrent episodes of severe swelling.Rio Tinto was 1.4% higher after HSBC raised the miner to Buy from Hold, Berkeley Group was down 1.2%, extending Wednesday's losses when it had said the housing market in the London and South East region has remained subdued. United Utilities was down 3.3% as the stock went ex-dividend, meaning new buyers no longer qualify for the latest payout. Land Securities, also ex-dividend, was down 1.4%.In the FTSE 250, Dixons was up 2.5% as investors were pleased the electricals retailer managed to clear the low bar it set for itself in May for the release of its annual results.Dixons on Thursday said like-for-like revenue rose 4% in the 12 months to April 28, as statutory revenue grew 3% to GBP10.53 billion from GBP10.25 billion last year, but pretax profit slumped to GBP289 million from GBP404 million.The trading update in late May saw the electronics retailer's shares lose around 20% in one day. The FTSE 250 constituent had warned that headline pretax profit for the year just ended would slump to GBP382 million from GBP500 million the year prior - in line with the figure reported on Thursday.For the year ahead, Dixons - also as previously announced last month - said headline profit is expected to be around GBP300 million."In short, pleasingly the UK performance was no worse than feared, but following the recent unscheduled trading update in May, there is little new news in today's prelims and guidance for next year," said analysts at Investec of the Dixons results.Crest Nicholson was up 2.4% after Liberum started the housebuilder with a Buy rating.

Also benefiting from broker actions was CYBG, 2.7% higher after JPMorgan raised the challenger bank to Neutral from Underweight. JPMorgan at the same time lowered CYBG's bid target Virgin Money to Neutral from Overweight. Virgin Money shares were up 1.3% early Thursday nonetheless, as CYBG's offer for Virgin Money is all in CYBG shares and so improves with CYBG's stock price.Elsewhere on the Main Market, Chemring was up 3.4% as interim revenue fell 8% to GBP229.3 million, though the defence countermeasures maker swung to a pretax profit of GBP4.3 million from a loss of GBP6.8 million last year.The company said the swing to profit in the half year to April 30 was a result of an improved underlying performance as well as reduced restructuring costs. It said underlying pretax profit rose 31% to GBP14.8 million from GBP11.3 million.Chemring declared an interim dividend of 1.1p per share, up 10% on last year's 1.0p. The firm said its full-year expectations remain unchanged, with approximately 80% of expected second half revenue either in the current order book or delivered to date.In focus in the UK on Thursday will be the BoE's meeting, in which no change to monetary policy is expected.There will not be a press conference with BoE Governor Mark Carney immediately after the decision, but he will give a speech at the Lord Mayor's bankers and merchants dinner at Mansion House in the evening at 2115 BST.Sterling was quoted at USD1.3137 early Thursday ahead of the BoE, lower than USD1.3201 at the London equities close on Wednesday.Analysts at ING said the pound is likely to be "fairly unaffected" following the BoE decision due to the likelihood of a "fairly vague policy signal"."With Brexit politics and the short-term economic backdrop both highly fragile, we think the MPC will feel little need to send any pre-committing rate hike signal this month," said ING.In mainland Europe, the CAC 40 in Paris was up 0.3% while the DAX 30 in Frankfurt was flat early Thursday.In Asia on Thursday, the Japanese Nikkei 225 index closed up 0.6%. In China, the Shanghai Composite closed down 1.4%, while the Hang Seng index in Hong Kong is down 1.2%.In the economic events calendar on Thursday there are UK public sector borrowing figures at 0930 BST, US initial and continuing jobless claims at 1330 BST and the housing price index at 1400 BST.
More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.